BA
SLXP

Boston Advisors’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Boston Advisors’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-32,275
Closed -$3.98M – 608
2014
Q2 		$3.98M Buy
32,275
+6,525
+25% +$721K 0.17% 160
2014
Q1 		$2.67M Buy
+25,750
New +$2.64M 0.12% 185

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Boston Advisors's SLXP Position: Q3 2014 in Review

Boston Advisors sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q3 2014, closing a stake of 32,275 shares — an estimated $3.98M sold.

Boston Advisors first reported a position in SLXP in Q1 2014 and held it in 2 quarters. The position peaked at $3.98M in Q2 2014. 348 funds tracked by Wall St. Rank hold SLXP as of Q3 2014.

  • Boston Advisors reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q3 2014 after selling out during the quarter.
  • Boston Advisors sold 32,275 SALIX PHARMACEUTICALS LTD DEL shares in Q3 2014, an estimated $3.98M.
  • Boston Advisors first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q1 2014 and held it in 2 quarters.
  • Boston Advisors's SALIX PHARMACEUTICALS LTD DEL position peaked at $3.98M in Q2 2014.
  • 348 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q3 2014.

Based on Boston Advisors's 13F filing for Q3 2014, filed 22 Oct 2014.